Tuesday, 18 November 2014
NeuroTronik Limited has closed on the second tranche of its 2013 Series A financing. This funding results from the excellent progress made thus far in the development of the technology, therapy, and company.
NeuroTronik is developing a novel neuromodulation therapy, for use in hospitals, to treat acute heart failure syndrome. Having successfully deployed the therapy in canines and having achieved a positive initial therapy signal in humans, this funding tranche is deployed to demonstrate the therapy in humans during 2015. Series B Preferred Stock financing is slated immediately thereafter. That financing is designed to resource commercial system development, clinical trials, market approval, and initial commercialization in Europe.